Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 12, 2011, Pages 1359-1366

  Singh, Sonal ^a   Loke, Yoon K ^b   Spangler, John G ^c   Furberg, Curt D ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO; VARENICLINE;

ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG DOSE TITRATION; DRUG SAFETY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; NICOTINE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIDE EFFECT; SMOKELESS TOBACCO; SMOKING CESSATION; SUDDEN DEATH; SYSTEMATIC REVIEW;

EID: 80052549139     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110218     Document Type: Article

References (35)

1. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011;(2): CD006103.
2. Mihalak K.B., Carroll F.I., Luetje C.W. Varenicline is a partial agonist at alpha 4 beta 2 and a full agonist at alpha 7 neuronal nico tinic receptors. Mol Pharmacol 2006;70:801-805 (Pubitemid 44268437)
3. Wang J., Wang X., Irnaten M., et al. Endogenous acetylcholine and nicotine activation enhances GABAergic and glycinergic inputs to cardiac vagal neurons. J Neurophysiol 2003;89:2473-2481 (Pubitemid 36570212)
4. Lindenblatt N., Platz U., Hameister J., et al. Distinct effects of acute and chronic nicotine application on microvascular thrombus formation and endothelial function in male and female mice. Langenbecks Arch Surg 2007;392:285-295 (Pubitemid 46675808)
5. Josefberg H. Approval package for: application number NDA 21-928 [clinical safety review: varenicline tartrate]. Rockville (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2006. p. 277, 402. Available: www .accessdata .fda .gov /drugsatfda -docs /nda /2006 /021928 -s000 -Chantix -MedR .pdf (ac cessed 2011 Apr. 14).
6. Highlights of prescribing information: Chantix® (varenicline). New York (NY): Pfizer; 2006. Available: www.pfizer .com /files /products/uspi- chantix.pdf (ac cessed 2011 Apr. 14).
7. Montastruc G., Degand B., Montastruc J.L., et al. Cardiac arrest with varenicline: A case report [article in French]. Therapie 2009; 64: 65-66
8. Anthonisen N.R., Skeans M.A., Wise R.A., et al.; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med 2005;142:233-239 (Pubitemid 40216240)
9. Rigotti N.A., Pipe A.L., Benowitz N.L., et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010;121:221-229
10. Faessel H.M., Obach R.S., Rollema H., et al. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 2010;49:799-816.
11. Dacosta A., Guy J.M., Tardy B., et al. Myocardial infarction and nicotine patch: A contributing or causative factor? Eur Heart J 1993;14:1709-1711 (Pubitemid 24041105)
12. Loke Y.K., Price D., Herxheimer A. Adverse effects. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated 2008 Feb.]. Chichester (UK): The Cochrane Collaboration; 2008. Available: www.cochrane-handbook.org (accessed 2011 Jan. 27).
13. Bradburn M.J., Deeks J.J., Berlin J.A., et al. Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77. (Pubitemid 46099417)
14. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560 (Pubitemid 37088507)
15. Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-1375 (Pubitemid 38594143)
16. Protocol A3051080. New York (NY): Pfizer; 2009. Available: www.clinicalstudyresults.org/documents/company-study -10429 -0.pdf (ac cessed 2011 Apr. 14).
17. Protocol A3051095. New York (NY): Pfizer; 2009. Available: www.clinicalstudyresults.org/documents/company-study -10818 -0.pdf (ac cessed 2011 Apr. 14).
18. Fagerström K., Gilljam H., Metcalfe M., et al. Stopping smokeless tobacco with varenicline: Randomised double blind placebo controlled trial. BMJ 2010;341:c6549.
19. Gonzales D., Rennard S.I., Nides M., et al.; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006;296:47-55.
20. Jorenby D.E., Hays J.T., Rigotti N.A., et al.; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006;296:56-63.
21. Nakamura M., Oshima A., Fujimoto Y., et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo- controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-1056 (Pubitemid 47198885)
22. Niaura R., Hays J.T., Jorenby D.E., et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: A randomized controlled trial. Curr Med Res Opin 2008;24:1931-1941
23. Nides M., Oncken C., Gonzales D., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion- controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-1568 (Pubitemid 44232363)
24. Oncken C., Gonzales D., Nides M., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166:1571-1577 (Pubitemid 44232364)
25. Tashkin D.P., Rennard S., Hays J.T.,et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: A randomized controlled trial. Chest. 2011;139:591-599
26. Tonstad S., Tonnesen P., Hajek P., et al.; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 2006; 296: 64-71.
27. Tsai S.T., Cho H.J., Cheng H.S., et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29: 1027-1039
28. Williams K.E., Reeves K.R., Billing C.B. Jr, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801. (Pubitemid 46646499)
29. Aubin H.J., Bobak A., Britton J.R., et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax 2008;63:717-724
30. Granger C.B., Vogel V., Cummings S.R., et al. Do we need to adjudicate major clinical events? Clin Trials 2008;5:56-60. (Pubitemid 351412373)
31. Chapman S., MacKenzie R. The global research neglect of unassisted smoking cessation: Causes and consequences. PLoS Med 2010;7:e1000216.
32. Moore T.J., Glenmullen J., Furberg C.D. Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother 2010;44:1389-1394
33. Mooney M., White T., Hatsukami D. The blind spot in the nicotine replacement therapy literature: Assessment of the double-blind in clinical trials. Addict Behav 2004;29:673-684 (Pubitemid 38591574)
34. Carpenter D., Zucker E.J., Avorn J. Drug-review deadlines and safety problems. N Engl J Med 2008;358:1354-1361 (Pubitemid 351468412)
35. FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Rockville (MD): US Food and Drug Administration; 2011. Available: www.fda.gov /Drugs /DrugSafety /ucm259161.htm (ac cessed 2011 June 23).